ZA201902629B - Selective inhibitor of exon 20 insertion mutant egfr - Google Patents
Selective inhibitor of exon 20 insertion mutant egfrInfo
- Publication number
- ZA201902629B ZA201902629B ZA2019/02629A ZA201902629A ZA201902629B ZA 201902629 B ZA201902629 B ZA 201902629B ZA 2019/02629 A ZA2019/02629 A ZA 2019/02629A ZA 201902629 A ZA201902629 A ZA 201902629A ZA 201902629 B ZA201902629 B ZA 201902629B
- Authority
- ZA
- South Africa
- Prior art keywords
- exon
- selective inhibitor
- mutant egfr
- insertion mutant
- antitumor agent
- Prior art date
Links
- 230000037431 insertion Effects 0.000 title abstract 2
- 238000003780 insertion Methods 0.000 title abstract 2
- 108060006698 EGF receptor Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016213072 | 2016-10-31 | ||
| PCT/JP2017/037186 WO2018079310A1 (ja) | 2016-10-31 | 2017-10-13 | エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201902629B true ZA201902629B (en) | 2023-12-20 |
Family
ID=62024991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/02629A ZA201902629B (en) | 2016-10-31 | 2019-04-25 | Selective inhibitor of exon 20 insertion mutant egfr |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11857513B2 (ja) |
| EP (1) | EP3533449B1 (ja) |
| JP (1) | JP6896755B2 (ja) |
| KR (1) | KR102639585B1 (ja) |
| CN (1) | CN110191711B (ja) |
| AU (1) | AU2017350440B2 (ja) |
| BR (1) | BR112019008374A2 (ja) |
| CA (1) | CA3041015A1 (ja) |
| DK (1) | DK3533449T3 (ja) |
| ES (1) | ES2955832T3 (ja) |
| FI (1) | FI3533449T3 (ja) |
| HU (1) | HUE063712T2 (ja) |
| IL (1) | IL266239B2 (ja) |
| JO (1) | JOP20190073A1 (ja) |
| MX (1) | MX2019004969A (ja) |
| PH (1) | PH12019500957A1 (ja) |
| PL (1) | PL3533449T3 (ja) |
| PT (1) | PT3533449T (ja) |
| SG (1) | SG11201903875QA (ja) |
| TW (1) | TWI774699B (ja) |
| WO (1) | WO2018079310A1 (ja) |
| ZA (1) | ZA201902629B (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| AU2019417691A1 (en) * | 2018-12-28 | 2021-07-22 | Taiho Pharmaceutical Co., Ltd. | L718 and/or L792 mutant treatment-resistant EGFR inhibitor |
| BR112021015813A2 (pt) | 2019-02-15 | 2021-10-13 | Taiho Pharmaceutical Co., Ltd. | Derivado de 7h-pirrolo[2,3-d]pirimidina-4-amina |
| WO2021057796A1 (zh) * | 2019-09-29 | 2021-04-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的稠合三环衍生物及其组合物及用途 |
| CN113861195B (zh) * | 2020-06-30 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种多稠环egfr抑制剂及其制备方法和应用 |
| WO2022007841A1 (zh) * | 2020-07-09 | 2022-01-13 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN115785107A (zh) * | 2022-12-15 | 2023-03-14 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| CA2601766A1 (en) | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| DK1800675T3 (da) | 2005-12-23 | 2011-09-05 | Nutricia Nv | Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens |
| CA2767556C (en) | 2009-07-10 | 2017-11-28 | Taiho Pharmaceutical Co., Ltd. | Azabicyclo compound and salt thereof |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| CA2824013A1 (en) | 2011-01-07 | 2012-07-12 | Taiho Pharmaceutical Co., Ltd. | Novel bicyclic compound or salt thereof |
| JP5878178B2 (ja) | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | １，２，４−トリアジン−６−カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| WO2013118817A1 (ja) | 2012-02-07 | 2013-08-15 | 大鵬薬品工業株式会社 | キノリルピロロピリミジン化合物又はその塩 |
| US8889666B2 (en) | 2012-02-23 | 2014-11-18 | Taiho Pharmaceutical Co., Ltd. | Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof |
| KR20150119401A (ko) | 2013-02-22 | 2015-10-23 | 다이호야쿠힌고교 가부시키가이샤 | 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물 |
| JP6161705B2 (ja) | 2013-08-22 | 2017-07-12 | 大鵬薬品工業株式会社 | 新規キノリン置換化合物 |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| AU2015277786B2 (en) | 2014-06-19 | 2019-04-18 | Takeda Pharmaceutical Company Limited | Heteroaryl compounds for kinase inhibition |
| JP6583614B2 (ja) | 2015-05-11 | 2019-10-02 | 大同特殊鋼株式会社 | アーク炉の電極折損防止装置 |
| CA3074418C (en) | 2017-09-01 | 2024-04-23 | Taiho Pharmaceutical Co., Ltd. | Exon 18 and/or exon 21 mutant egfr selective inhibitor |
-
2017
- 2017-06-16 JO JOP/2019/0073A patent/JOP20190073A1/ar unknown
- 2017-10-13 AU AU2017350440A patent/AU2017350440B2/en active Active
- 2017-10-13 PT PT178649752T patent/PT3533449T/pt unknown
- 2017-10-13 JP JP2018547565A patent/JP6896755B2/ja active Active
- 2017-10-13 HU HUE17864975A patent/HUE063712T2/hu unknown
- 2017-10-13 TW TW106135203A patent/TWI774699B/zh active
- 2017-10-13 DK DK17864975.2T patent/DK3533449T3/da active
- 2017-10-13 PL PL17864975.2T patent/PL3533449T3/pl unknown
- 2017-10-13 BR BR112019008374A patent/BR112019008374A2/pt unknown
- 2017-10-13 CN CN201780067762.5A patent/CN110191711B/zh active Active
- 2017-10-13 EP EP17864975.2A patent/EP3533449B1/en active Active
- 2017-10-13 SG SG11201903875QA patent/SG11201903875QA/en unknown
- 2017-10-13 WO PCT/JP2017/037186 patent/WO2018079310A1/ja unknown
- 2017-10-13 KR KR1020197015270A patent/KR102639585B1/ko active IP Right Grant
- 2017-10-13 ES ES17864975T patent/ES2955832T3/es active Active
- 2017-10-13 CA CA3041015A patent/CA3041015A1/en active Pending
- 2017-10-13 IL IL266239A patent/IL266239B2/en unknown
- 2017-10-13 FI FIEP17864975.2T patent/FI3533449T3/fi active
- 2017-10-13 MX MX2019004969A patent/MX2019004969A/es unknown
- 2017-10-31 US US16/345,792 patent/US11857513B2/en active Active
-
2019
- 2019-04-25 ZA ZA2019/02629A patent/ZA201902629B/en unknown
- 2019-04-29 PH PH12019500957A patent/PH12019500957A1/en unknown
-
2023
- 2023-11-17 US US18/512,528 patent/US20240148734A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500957A1 (en) | Selective inhibitor of exon 20 insertion mutant egfr | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
| MX2020012261A (es) | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. | |
| MX2018004832A (es) | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. | |
| MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| EA201890768A3 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| EA201692472A1 (ru) | Соединения для лечения рака мозга | |
| MX2023010882A (es) | Compuestos y composiciones para el tratamiento de trastornos hematológicos. | |
| AU2016246521A8 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| MY188089A (en) | Prodrugs for the treatment of cancer | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MX2019010149A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
| JOP20200044A1 (ar) | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 | |
| PH12017500881B1 (en) | Aurora a kinase inhibitor | |
| MX2020006297A (es) | Variantes de cd19. | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| WO2015143424A3 (en) | Methods of treating cancer | |
| AU2018380132A8 (en) | Tubulin inhibitors | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| PH12018501943A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
| MX2016016507A (es) | Composiciones y metodos para tratar canceres. | |
| MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof |